help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Order Full text via Infotrieve
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Joseph, J. T.
Right arrow Articles by Louis, D. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Joseph, J. T.
Right arrow Articles by Louis, D. N.

American Journal of Pathology, Vol 147, 1450-1455, Copyright © 1995 by American Society for Investigative Pathology


REGULAR ARTICLES

NF2 gene analysis distinguishes hemangiopericytoma from meningioma

JT Joseph, DK Lisle, LB Jacoby, W Paulus, R Barone, ML Cohen, WH Roggendorf, JM Bruner, JF Gusella and DN Louis
Molecular Neuro-Oncology Laboratory, Massachusetts General Hospital, Boston, USA.

The histogenesis of dural-based or "central" hemangiopericytomas (cHPCs) remains controversial. Some authors consider these tumors variants of meningiomas while others consider them akin to peripheral hemangiopericytomas (pHPCs). Meningiomas frequently have mutations in the neurofibromatosis 2 (NF2) gene, providing a molecular marker for meningiomas and other NF2-related tumors. We therefore analyzed the NF2 gene in cHPCs, pHPCs, and meningiomas to determine whether cHPCs are more similar at the molecular genetic level to meningiomas or pHPCs. Using paraffin-embedded archival material from 28 cHPCs (including three primary and recurrent tumors), 10 pHPCs, and 26 meningiomas, we scanned all 17 exons of the NF2 gene and flanking intronic sequences for mutations with single strand conformation polymorphism analysis and DNA sequencing. No NF2 mutations were found in either cHPCs or pHPCs, whereas 35% of meningiomas had NF2 gene alterations (P < 0.001). The NF2 gene mutations in meningiomas were all truncating mutations, consistent with previous studies. Our findings suggest that cHPCs are distinct from meningiomas at the molecular genetic level and support prior clinico-pathological data that distinguish these tumor-entities.


This article has been cited by other articles:


Home page
Cancer Res.Home page
K. Ueki, C. Wen-Bin, Y. Narita, A. Asai, and T. Kirino
Tight Association of Loss of Merlin Expression with Loss of Heterozygosity at Chromosome 22q in Sporadic Meningiomas
Cancer Res., December 1, 1999; 59(23): 5995 - 5998.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Society for Investigative Pathology.